Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC

被引：3
|
作者：
Mazieres, J. [1 ]
Novello, S. [2 ]
De Castro, J. [3 ]
Migliorino, M. R. [4 ]
Helland, A. [5 ,6 ]
Dziadziuszko, R. [7 ]
Griesinger, F. [8 ]
Wolf, J. [9 ]
Zeaiter, A. [10 ]
Cardona, A. [10 ]
Balas, B. [10 ]
Karagiannis, T. [11 ,12 ]
Chlistalla, M. [10 ]
Smoljanovic, V. [10 ]
Oh, I. [12 ]
机构：
[1] Toulouse Univ Hosp, Toulouse, France
[2] Univ Turin, Dept Oncol, Turin, Italy
[3] Univ Hosp La Paz, Dept Med Oncol, Madrid, Spain
[4] San Camillo Forlanini Hosp, Dept Lung Dis, Rome, Italy
[5] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway
[6] Radiumhosp, Oslo Univ Hosp, Inst Canc Res, Dept Oncol, Oslo, Norway
[7] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland
[8] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Oncol, Oldenburg, Germany
[9] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany
[10] F Hoffmann La Roche Ltd, Basel, Switzerland
[11] Genentech Inc, San Francisco, CA 94080 USA
[12] Chonnam Natl Univ, Hwasun Hosp, Jeonnam, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Alectinib; chemotherapy; NSCLC;
D O I：
10.1016/j.jtho.2017.09.667
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-013
引用
收藏
页码：S1897 / S1897
页数：1
相关论文
共 50 条
  • [41] Patient-reported outcomes from the phase III prostate HYPRO trial: urinary toxicity
    Wortel, R. C.
    Incrocci, L.
    Pos, F. J.
    Smeenk, R. J.
    Krol, A. D. G.
    Aluwini, S.
    Witte, M. G.
    Heijmen, B. J. M.
    Heemsbergen, W. D.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S295 - S297
  • [42] Patient-reported outcomes from the Phase III IMpassion031 trial of neoadjuvant atezolizumab plus chemotherapy in early triple-negative breast cancer
    Mittendorf, Elizabeth
    Harbeck, Nadia
    Zhang, Hong
    Saji, Shigehira
    Jung, Kyung Hae
    Patel, Sheetal
    Patel, Shilpen
    Anh Nguyen Duc
    Liste-Hermoso, Mario
    Chui, Stephen Y.
    Barrios, Carlos H.
    CANCER RESEARCH, 2021, 81 (04)
  • [43] Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer
    Reck, Martin
    Wehler, Thomas
    Orlandi, Francisco
    Nogami, Naoyuki
    Barone, Carlo
    Moro-Sibilot, Denis
    Shtivelband, Mikhail
    Gonzalez Larriba, Jose Luis
    Rothenstein, Jeffrey
    Fruh, Martin
    Yu, Wei
    Deng, Yu
    Coleman, Shelley
    Shankar, Geetha
    Patel, Hina
    Kelsch, Claudia
    Lee, Anthony
    Piault, Elisabeth
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (22) : 2530 - +
  • [44] Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK plus non-small-cell lung cancer (NSCLC)
    Barlesi, F.
    Dingemans, A-M. C.
    Yang, J. C-H.
    Ou, S-H. I.
    Ahn, J. S.
    De Petris, L.
    Hughes, B.
    Lena, H.
    Bordogna, W.
    Golding, S.
    Morcos, P. N.
    Balas, B.
    Zeaiter, A.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK plus non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo)
    Solomon, B. J.
    Wu, Y-L.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Ahn, J. S.
    Horinouchi, H.
    Hochmair, M. J.
    de Marinis, F.
    Migliorino, M. R.
    Kurochkin, A.
    Harputluoglu, H.
    Planchard, D.
    Korphaisarn, K.
    Han, J-Y.
    Lohmann, T.
    Gavaldon, A. Cardona
    Archer, V. R.
    Nowicka, M.
    Noe, J.
    ANNALS OF ONCOLOGY, 2024, 35 : S775 - S775
  • [46] Patients′ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
    Reck, M.
    Granados, A. L. O. Ortega
    de Marinis, F.
    Shen, Q.
    Boklage, S. H.
    Dabrowski, C.
    Cho, L.
    Meyers, O.
    ANNALS OF ONCOLOGY, 2023, 34
  • [47] Patients' perspective on tolerability of dostarlimab in NSCLC: patient-reported outcomes from the Phase II PERLA trial
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Shen, Qin
    Boklage, Susan
    Dabrowski, Christine
    Cho, Lillian
    Meyers, Oren
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 130 - 130
  • [48] Patient-reported Outcomes in Oropharyngeal Cancer Treated With Definitive Chemoradiation vs. Surgery With Postoperative Radiation With or Without Chemotherapy
    McDonald, M. W.
    Bates, J. E.
    Patel, M. R.
    Boyce, B. J.
    Rudra, S.
    Kaka, A. S.
    Steuer, C.
    Shin, D. M.
    Tian, S.
    Nathan, M. R.
    Waller, J. M.
    Thomas, S. E.
    Remick, J. S.
    Barrett, T.
    Ottenstein, L.
    Saba, N. F.
    Stokes, W. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 113 (01): : E2 - E2
  • [49] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    Cella, D.
    Escudier, B.
    Rini, B.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Motzer, R.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1571 - 1578
  • [50] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    D Cella
    B Escudier
    B Rini
    C Chen
    H Bhattacharyya
    J Tarazi
    B Rosbrook
    S Kim
    R Motzer
    British Journal of Cancer, 2013, 108 : 1571 - 1578
12345